<DOC>
	<DOCNO>NCT00725634</DOCNO>
	<brief_summary>Phase 1 study determine safety , tolerability , dose-limiting toxicity ( DLTs ) , recommend Phase 2 dose AV-299 administer IV monotherapy patient relapse refractory solid tumor , lymphoma , multiple myeloma . The study also determine safety , tolerability DLTs AV-299 combination erlotinib patient relapse refractory solid tumor .</brief_summary>
	<brief_title>A Phase 1 Dose-Escalation Study Advanced Solid Tumors , Lymphomas Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Diagnosis advance solid tumor malignancy lymphoma ( nonHodgkin 's Hodgkin 's lymphoma ) . Histological cytological evidence malignancy . Advanced malignancy , metastatic unresectable , recur progress follow standard therapy fail standard therapy ; standard therapy currently exist , subject candidate , unwilling undergo , standard therapy . Disease currently amenable curative surgical intervention . ECOG performance status 01 . Subjects performance status 2 consider discussion investigator medical monitor . 18 year old , either sex , race . Subject ( and/or parent/guardian subject otherwise unable provide independent consent , acceptable approve site and/or site 's IRB ) must willing give write informed consent able adhere dose visit schedule . Female subject childbearing potential must negative pregnancy test within 5 day prior first dose study drug . Female subject childbearing potential male subject whose sexual partner childbearing potential must agree abstain sexual intercourse use effective method contraception study 60 day last dose AV299 ( formerly SCH 900105 ) . Examples effective method contraception include , limited , oral contraceptive double barrier method condom plus spermicide condom plus diaphragm . Adequate hematologic function evidence Hg ≥ 9g/dL , WBC ≥ 3000 per mm3 , ANC ≥ 1500 per mm3 platelet count ≥ 100,000 per mm3 . Adequate hepatic function evidence serum bilirubin level ≤1.5 × ULN ( except know Gilbert 's Syndrome ) For subject doseescalation cohorts Phase 1b evaluation AV299 ( formerly SCH 900105 ) combination erlotinib : Serum AST/ALT level ≤3 × ULN reference laboratory For subject RP2D safety expansion cohort : Without know hepatic metastasis serum AST/ALT level ≤3 × ULN reference laboratory With know hepatic metastasis serum AST/ALT level ≤5 × ULN . Adequate renal function evidence serum creatinine level ≤ 1.5 × ULN calculate creatinine clearance &gt; 60 mL/min . Adequate coagulation function evidence PTT ≤ 1.5 × ULN INR ≤ 1.5 × ULN Recovery effect prior surgery , radiotherapy , systemic antineoplastic therapy . Subjects abnormal liver function test ( LFTs ) screen Hepatitis B C within past 6 month prior study enrollment , need screen Hepatitis B C enrol screen negative . Diagnosis Main Criteria Inclusion Multiple Myeloma Exploratory Cohort Subjects Included Diagnosis symptomatic relapse refractory multiple myeloma . Note : For relapsed disease , subject must PD achieve least stable disease ≥ 1 cycle treatment ≥ 1 prior regimen . For refractory disease , subject must document evidence PD within 60 day ( measure end last cycle ) complete treatment last antimyeloma drug regimen use prior study entry . Measurable disease assess one following : Serum monoclonal protein ≥ 1.0 g/dL protein electrophoresis ; &gt; 200 mg monoclonal protein urine 24 hour electrophoresis ; Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa lambda free light chain ratio ; , Monoclonal bone marrow plasmacytosis ≥ 30 % ( evaluable disease ) . Note : All evaluation , measurable result screen , repeat indicated visit schedule schedule assessment , exception bone marrow plasmacytosis . Bone marrow plasmacytosis repeat disease/response assessment accord visit schedule schedule assessment measurable result screening . If serum urine Mproteins present , must follow order evaluate response . At least 2 prior therapy ECOG performance status 0 , 1 , 2 . 18 year old , either sex , race . Subject ( and/or parent/guardian subject otherwise unable provide independent consent , acceptable approve site and/or site 's IRB ) must willing give write informed consent able adhere dose visit schedule . Female subject childbearing potential must negative pregnancy test within 5 day prior first dose study drug . Female subject childbearing potential male subject whose sexual partner childbearing potential must agree abstain sexual intercourse use effective method contraception study 60 day last dose AV299 ( formerly SCH 900105 ) . Examples effective method contraception include , limited , oral contraceptive double barrier method condom plus spermicide condom plus diaphragm . Adequate hematologic function evidence Hg ≥ 9g/dL , ANC ≥ 1000 per mm3 , platelet count ≥ 50,000 per mm3 . Screening platelet count independent platelet transfusion ≥ 2 week . Adequate hepatic function evidence serum bilirubin level ≤ 1.5 × ULN ( except know Gilbert 's Syndrome ) serum AST ALT level ≤ 3 × ULN . Adequate renal function evidence serum creatinine level ≤ 3.0 mg/dL . Adequate coagulation function evidence PTT ≤ 1.5 × ULN INR ≤ 1.5 × ULN . All previous cancer chemotherapy , include radiation , hormonal therapy , surgery , must discontinue ≥ 2 week prior first dose study drug . Subjects abnormal liver function test ( LFTs ) screen Hepatitis B C within past 6 month prior study enrollment , need screen Hepatitis B C enrol screen negative . Subject willing provide blood feasible , bone marrow sample research purpose . Women breastfeed , pregnant , intend become pregnant . Subjects primary CNS malignancy symptomatic CNS metastasis , exception subject glioblastoma multiforme may enrol RP2D Safety Expansion Cohort Phase 1b evaluation AV299 ( formerly SCH 900105 ) combination erlotinib . Subjects treat brain metastasis remain stable least 3 month without steroid allow . Subjects sign symptom history brain metastasis must CT MRI scan brain within 1 month prior first dose study drug . Subjects spinal cord nerve root compression complete treatment least 4 week prior first dose study drug stable without steroid treatment least 1 week prior first dose study drug allow . Subjects leptomeningeal metastasis allow . Hematologic malignancy lymphoma Any follow within 6 month prior administration study drug : Myocardial infarction ( MI ) , severe /unstable angina pectoris , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack seizure disorder . Serious and/or symptomatic active infection within 14 day prior first dose study drug . Subjects asymptomatic mild infection take short course antibiotic ( ie , UTI , bronchitis ) may allow discussion medical monitor . Baseline QTc interval follow per Bazett 's formula : Females &gt; 470 msec ; Males &gt; 450 msec . Persistent , unresolved CTCAE v3.0 Grade 2 high drugrelated toxicity ( except alopecia , erectile dysfunction , hot flash , decrease libido ) associate previous treatment . Inadequate recovery prior surgical procedure major surgical procedure perform within 4 week prior administration first dose major surgery within 3 week prior first dose study drug . Any medical psychiatric condition , opinion investigator , might interfere subject 's participation trial interfere interpretation trial result . Known Human Immunodeficiency Virus ( HIV ) infection know HIVrelated malignancy . Known active hepatitis B C. Known hypersensitivity component AV299 ( formerly SCH 900105 ) . Radiotherapy within 3 week prior first study drug administration . Inability comply protocol requirement participation clinical study . Any medication list table `` Prohibited Medications '' . Active alcohol abuse . Stem cell/bone marrow transplant within 6 month first dose study drug . Additional Exclusion Criteria Subjects Enrolled Phase 1b Evaluation AV299 ( formerly SCH 900105 ) Combination Erlotinib : Inability take oral medication Grade 2 high diarrhea baseline , inflammatory bowel disease Any gastrointestinal disorder may interfere absorption oral medication Acute onset new progressive pulmonary symptom , dyspnea , cough fever within 4 week prior first study treatment , diagnosis interstitial lung disease ( ILD ) Exclusion Multiple Myeloma Exploratory Cohort Women breastfeeding , pregnant , intend become pregnant . Active malignancy kind require likely require treatment within next 12 month , exception basal cell skin cancer , situ cervical cancer , situ breast cancer asymptomatic prostate cancer . Any following prior first dose study drug : POEMS ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) , plasma cell leukemia , Waldenstrom 's macroglobulinemia . Any follow within 6 month prior administration study drug : Myocardial infarction ( MI ) , severe /unstable angina pectoris , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack seizure disorder . Serious and/or symptomatic active infection within 14 day prior first dose study drug . Subjects asymptomatic mild infection take short course antibiotic ( ie , UTI , bronchitis ) may allow discussion medical monitor . Baseline QTc interval follow per Bazett 's formula : Females &gt; 470 msec ; Males &gt; 450 msec . Persistent , unresolved CTCAE v3.0 Grade 2 high drugrelated toxicity ( except alopecia , erectile dysfunction , hot flash , decrease libido ) associate previous treatment . Inadequate recovery prior surgical procedure major surgical procedure perform within 4 week prior administration first dose major surgery within 3 week prior first dose study drug . Any medical psychiatric condition , opinion investigator , might interfere subject 's participation trial interfere interpretation trial result . Known Human Immunodeficiency Virus ( HIV ) infection know HIVrelated malignancy . Known active hepatitis B C. Known hypersensitivity component AV299 ( formerly SCH 900105 ) . Radiotherapy within 3 week prior first study drug administration , except use palliative treatment pain control . Inability comply protocol requirement participation clinical study . Any medication list table `` Prohibited Medications '' . Active alcohol abuse . Maintenance steroid therapy &gt; 20 mg/day prednisone , &gt; 4 mg/day dexamethasone , &gt; 80 mg/day hydrocortisone , equivalent . NOTE : Maintenance steroid therapy ≤ 20 mg/day prednisone , ≤ 4 mg/day dexamethasone , ≤ 80 mg/day hydrocortisone , equivalent allow provide subject stable dose least 2 week prior first dose study drug dose adjust upwards 2 week prior first dose study drug . Prior therapy involve antiHGF antibody cMet small molecule inhibitor . Allogeneic stem cell/bone marrow transplant within 12 month first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Neoplasms ,</keyword>
	<keyword>Lymphoma ,</keyword>
	<keyword>Multiple Myeloma ,</keyword>
	<keyword>Neoplasms , Plasma Cell ,</keyword>
	<keyword>Neoplasms Histologic Type ,</keyword>
	<keyword>Lymphoproliferative Disorders ,</keyword>
	<keyword>Lymphatic Diseases , Immunoproliferative Disorders</keyword>
	<keyword>Immune System Diseases Hemostatic Disorders</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Paraproteinemias</keyword>
	<keyword>Blood Protein Disorders</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Hemorrhagic Disorders</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Protein Kinase Inhibitors</keyword>
	<keyword>Enzyme Inhibitors ,</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Pharmacologic Actions</keyword>
</DOC>